Drug-resistant tuberculosis: time for visionary political leadership.

[1]  H. S. Schaaf,et al.  Hearing loss in children treated for multidrug-resistant tuberculosis. , 2013, The Journal of infection.

[2]  N. Ford,et al.  Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis [Review article]. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  Rebecca Voelker,et al.  MDR-TB has new drug foe after fast-track approval. , 2013, JAMA.

[4]  K. Floyd,et al.  Multidrug-resistant tuberculosis in children: evidence from global surveillance , 2012, European Respiratory Journal.

[5]  D. van Soolingen,et al.  The added effect of thioridazine in the treatment of drug-resistant tuberculosis. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[6]  K. Floyd,et al.  Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert®MTB/RIF Weyer, , 2013 .

[7]  J. Kosterink,et al.  Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis , 2012, European Respiratory Journal.

[8]  H. Jenkins,et al.  Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country , 2012, European Respiratory Journal.

[9]  T. Holtz,et al.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes , 2012, European Respiratory Journal.

[10]  T. Cohen,et al.  Mixed-Strain Mycobacterium tuberculosis Infections and the Implications for Tuberculosis Treatment and Control , 2012, Clinical Microbiology Reviews.

[11]  V. Leimane,et al.  Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis , 2012, European Respiratory Journal.

[12]  Giovanni Sotgiu,et al.  Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB , 2012, European Respiratory Journal.

[13]  A. Diacon,et al.  14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial , 2012, The Lancet.

[14]  Salmaan Keshavjee,et al.  Tuberculosis, drug resistance, and the history of modern medicine. , 2012, The New England journal of medicine.

[15]  Marcos Burgos,et al.  Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients , 2012, PLoS medicine.

[16]  P. Bhatter,et al.  The Dragon and the Tiger: Realties in the Control of Tuberculosis , 2012, Interdisciplinary perspectives on infectious diseases.

[17]  Gee Young Suh,et al.  Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.

[18]  Yu Wang,et al.  National survey of drug-resistant tuberculosis in China. , 2012, The New England journal of medicine.

[19]  Carlos Martín,et al.  Long-term molecular surveillance of multidrug-resistant tuberculosis in Spain. , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[20]  N. Ford,et al.  Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[21]  A. Sandgren,et al.  Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement , 2012, European Respiratory Journal.

[22]  F. Blasi,et al.  Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones , 2012, European Respiratory Journal.

[23]  K. Floyd,et al.  Scaling up interventions to achieve global tuberculosis control: progress and new developments , 2012, The Lancet.

[24]  A. Spanevello,et al.  Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  T. Shim,et al.  Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis , 2012, European Respiratory Journal.

[26]  Xin Wang,et al.  Social Behaviour Risk Factors for Drug Resistant Tuberculosis in Mainland China: A Meta-Analysis , 2012, The Journal of international medical research.

[27]  Giovanni B Migliori,et al.  The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? , 2012, The Lancet.

[28]  Camilla Rodrigues,et al.  Totally drug-resistant tuberculosis in India. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  K. Floyd,et al.  Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. , 2012, Bulletin of the World Health Organization.

[30]  Alimuddin Zumla,et al.  Tackling the spread of drug-resistant tuberculosis in Europe , 2012, The Lancet.

[31]  T. Kirby.  Louisa Degenhardt: hooked on addiction research , 2012, The Lancet.

[32]  E. Oren,et al.  Multistate Outbreak of MDR TB Identified by Genotype Cluster Investigation , 2012, Emerging infectious diseases.

[33]  G. Cooke,et al.  International Spread of MDR TB from Tugela Ferry, South Africa , 2011, Emerging infectious diseases.

[34]  K. Kliiman,et al.  TB and M/XDR-TB infection control in European TB reference centres: the Achilles’ heel? , 2011, European Respiratory Journal.

[35]  D. Manissero,et al.  Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis , 2011, European Respiratory Journal.

[36]  A. Skrahina,et al.  Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk , 2011, European Respiratory Journal.

[37]  M. D. Granado,et al.  WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update , 2011, European Respiratory Journal.

[38]  Alimuddin Zumla,et al.  Tuberculosis in the UK—time to regain control , 2011, BMJ : British Medical Journal.

[39]  K. Blöndal,et al.  Countrywide management of pulmonary tuberculosis reverses increasing incidence. , 2011, The International Journal of Tuberculosis and Lung Disease.

[40]  J. Westenhouse,et al.  Reduced importation of tuberculosis after the implementation of an enhanced pre-immigration screening protocol. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[41]  T. Cohen,et al.  Multiple Introductions of Multidrug-Resistant Tuberculosis into Households, Lima, Peru , 2011, Emerging infectious diseases.

[42]  M. Raviglione,et al.  Preventing and managing antimicrobial resistance: imperative for chest physicians , 2011, European Respiratory Journal.

[43]  K. Ijaz,et al.  Tuberculosis Outbreak Investigations in the United States, 2002–2008 , 2011, Emerging infectious diseases.

[44]  H. S. Schaaf,et al.  Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. , 2011, Paediatric respiratory reviews.

[45]  P. Farmer,et al.  Picking up the pace--scale-up of MDR tuberculosis treatment programs. , 2010, The New England journal of medicine.

[46]  T. Lancet.  The Global Fund: a bleak future ahead , 2010, The Lancet.

[47]  K. Floyd,et al.  MDR tuberculosis--critical steps for prevention and control. , 2010, The New England journal of medicine.

[48]  A. Van Deun,et al.  Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. , 2010, American journal of respiratory and critical care medicine.

[49]  G. Migliori,et al.  Tuberculosis on the move , 2010, The Lancet.

[50]  Alimuddin Zumla,et al.  Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action , 2010, The Lancet.

[51]  D. Falzon,et al.  Harmonisation of TB control in the WHO European region: the history of the Wolfheze Workshops , 2010, European Respiratory Journal.

[52]  R. Woosley,et al.  New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[53]  E. Graviss,et al.  A major subgroup of Beijing family Mycobacterium tuberculosis is associated with multidrug resistance and increased transmissibility , 2010, Epidemiology and Infection.

[54]  V. Baumanis,et al.  Recent nosocomial transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[55]  A. Nunn.  What is the role of clinical trials for the treatment of tuberculosis and what are the alternatives? , 2010, The International Journal of Tuberculosis and Lung Disease.

[56]  T. Sudarsanam,et al.  Risk Factors for MDR and XDR-TB in a Tertiary Referral Hospital in India , 2010, PloS one.

[57]  T. Holtz,et al.  Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[58]  Gavin Churchyard,et al.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis. , 2009, The New England journal of medicine.

[59]  J. Fitzgerald,et al.  Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis , 2009, PloS one.

[60]  N. Zarinfar,et al.  EPIDEMIOLOGY OF TUBERCULOSIS IN ARAK, IRAN , 2009 .

[61]  Parissa Farnia,et al.  Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. , 2009, Chest.

[62]  H. Ahasan,et al.  Extensively Drug-resistant Tuberculosis(XDR-TB) , 2009 .

[63]  F. Drobniewski,et al.  Extensively drug-resistant tuberculosis in the UK: 1995 to 2007 , 2009, Thorax.

[64]  Evan W. Orenstein,et al.  Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. , 2009, The Lancet. Infectious diseases.

[65]  M. Kruijshaar,et al.  The influence of socio-economic deprivation on tuberculosis treatment delays in England, 2000–2005 , 2008, Epidemiology and Infection.

[66]  Sonya S. Shin,et al.  Treating Multidrug‐Resistant Tuberculosis in Tomsk, Russia , 2008, Annals of the New York Academy of Sciences.

[67]  F. Drobniewski,et al.  Increasing antituberculosis drug resistance in the United Kingdom: analysis of national surveillance data , 2008, BMJ : British Medical Journal.

[68]  K. Castro,et al.  Randomized Trials to Optimize Treatment of Multidrug-Resistant Tuberculosis , 2007, PLoS medicine.

[69]  T. Holtz,et al.  HIV infection and multidrug-resistant tuberculosis: the perfect storm. , 2007, The Journal of infectious diseases.

[70]  Guy Thwaites,et al.  Beijing Genotype of Mycobacterium tuberculosis Is Significantly Associated with Human Immunodeficiency Virus Infection and Multidrug Resistance in Cases of Tuberculous Meningitis , 2006, Journal of Clinical Microbiology.

[71]  J. Mukherjee,et al.  Multidrug-resistant Tuberculosis Management in Resource-limited Settings , 2006, Emerging infectious diseases.

[72]  B. Bıcakçı,et al.  Side effects associated with the treatment of multidrug-resistant tuberculosis. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[73]  D. Curran‐Everett,et al.  Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[74]  J. Nosanchuk,et al.  Tuberculosis in New York city: recent lessons and a look ahead. , 2004, The Lancet. Infectious diseases.

[75]  F. Drobniewski,et al.  Outbreak of isoniazid resistant tuberculosis in north London , 2002, Thorax.

[76]  C. Braden,et al.  The epidemiology of tuberculosis in the United States. , 1997, Clinics in chest medicine.

[77]  T. Frieden,et al.  Tuberculosis in New York City--turning the tide. , 1995, The New England journal of medicine.

[78]  D. Snider,et al.  Epidemiology of tuberculosis in the United States, 1985 through 1992. , 1994, JAMA.

[79]  D. Snider,et al.  Epidemiology of tuberculosis in the United States. , 1989, Epidemiologic reviews.

[80]  G W Comstock,et al.  Epidemiology of tuberculosis. , 1982, The American review of respiratory disease.

[81]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[82]  N. Ford,et al.  Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[83]  A. Hesseling,et al.  Retooling existing tuberculosis drugs for children. , 2013, Clinical Infectious Diseases.

[84]  S. Dorman,et al.  A national infection control evaluation of drug-resistant tuberculosis hospitals in South Africa. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[85]  Tuberculosis outbreak associated with a homeless shelter - Kane County, Illinois, 2007-2011. , 2012, MMWR. Morbidity and mortality weekly report.

[86]  P. Zucs,et al.  Tuberculosis surveillance and monitoring in Europe 2012. , 2012 .

[87]  R. English,et al.  Facing the reality of drug-resistant tuberculosis: challenges and potential solutions in India: summary of a joint workshop by the Institute of Medicine, the Indian National Science Academy, and the Indian Council of Medical Research. , 2012 .

[88]  W. Bishai,et al.  Extensively drug-resistant tuberculosis. , 2009, The Lancet. Infectious diseases.

[89]  V. Robison,et al.  Trends in tuberculosis--United States, 2008. , 2009, MMWR. Morbidity and mortality weekly report.

[90]  L. Tanoue.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa , 2008 .

[91]  J. Gerberding,et al.  Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. , 2006, MMWR. Morbidity and mortality weekly report.

[92]  National action plan to combat multidrug-resistant tuberculosis. , 1992, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[93]  Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991. , 1991, MMWR. Morbidity and mortality weekly report.